Jennifer Robinson
Psychiatric/Mental Health · Houston, TXNPI 1255631412
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 825 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 825 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$956
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$863
- Sunovion Pharmaceuticals Inc.$862
- Vanda Pharmaceuticals Inc.$684
- plus $6K from 26 others
What the payments were for
- Food & beverage$12,195100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 93 | $1,563 |
| AbbVie | 173 | $1,185 |
| Otsuka America Pharmaceutical, Inc. | 60 | $956 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 63 | $863 |
| Sunovion Pharmaceuticals Inc. | 38 | $862 |
| Vanda Pharmaceuticals Inc. | 43 | $684 |
| Axsome Therapeutics, Inc. | 31 | $587 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $552 |
| Lundbeck LLC | 38 | $503 |
| Almatica Pharma LLC | 36 | $500 |
| Supernus Pharmaceuticals, Inc. | 10 | $497 |
| Ironshore Pharmaceuticals Inc. | 30 | $461 |
| Neurocrine Biosciences, Inc. | 22 | $456 |
| Teva Pharmaceuticals USA, Inc. | 27 | $432 |
| Noven Therapeutics, LLC | 18 | $332 |
| Neos Therapeutics, LP | 33 | $287 |
| E.r. Squibb & Sons, L.L.C. | 8 | $225 |
| Eisai Inc. | 13 | $221 |
| Corium, LLC | 13 | $219 |
| Idorsia Pharmaceuticals US Inc | 8 | $123 |
| Amgen | 1 | $116 |
| Jazz Pharmaceuticals Inc. | 5 | $104 |
| Johnson & Johnson | 5 | $92 |
| Collegium Pharmaceutical, Inc. | 4 | $73 |
| Adlon Therapeutics L.p. | 3 | $60 |
| Bausch Health US, LLC | 3 | $54 |
| Novo Nordisk | 3 | $53 |
| Aytu Biopharma, Inc. | 4 | $46 |
| Validus Pharmaceuticals LLC | 1 | $33 |
| Livanova USA, Inc. | 1 | $30 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,211 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 33 | $66,587 |
| VraylarCariprazine Hcl | 42 | $59,779 |
| Abilify MaintenaAripiprazole | 13 | $39,302 |
| RexultiBrexpiprazole | 27 | $38,692 |
| TrintellixVortioxetine Hydrobromide | 27 | $17,422 |
| Lurasidone Hcl | 47 | $12,129 |
| FetzimaLevomilnacipran Hcl | 15 | $7,257 |
| DepakoteDivalproex Sodium | 12 | $6,247 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 121 | $5,549 |
| Trazodone Hcl | 127 | $1,916 |
| Divalproex Sodium | 28 | $1,641 |
| Aripiprazole | 31 | $1,435 |
| Lamotrigine | 184 | $1,425 |
| Paliperidone ErPaliperidone | 13 | $1,301 |
| Duloxetine Hcl | 80 | $1,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $956 | $77,99440 claims |
| AbbVieVraylar, Fetzima | $1,185 | $67,03657 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $863 | $66,58733 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $552 | $17,42227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Houston
- Natalie TellezHouston$602K
- Britney PridgenHouston$57K
- Linzi LeightonHouston$16K
- Samantha SharpeHouston$14K
- Tracy HicksLongview$684K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.